Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 2 Endocrine 2 NET 1 Genitourinary 1

Conditions

Neuroendocrine Prostate Cancer 1

Interventions

Prednisone 122 Docetaxel 118 enzalutamide 101 pembrolizumab 96 Sunitinib 86 Leuprolide 84 Abiraterone Acetate 83 Nivolumab 78 Gemcitabine 76 bicalutamide 54 Radiotherapy 54 Goserelin 54 Bevacizumab 54 Cisplatin 52 Magnetic Resonance Spectroscopy 49 Everolimus 49 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 46 Sorafenib 40 Carboplatin 40 Paclitaxel 37 Radiosurgery 36 atezolizumab 35 abiraterone 33 pazopanib 32 cabozantinib 32 Ipilimumab 32 Axitinib 30 Cyclophosphamide 29 Androgen Antagonists 29 Radiation 28

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × AMG 757 × Genitourinary × Clear all

NCT04702737 2025-09-12

DeLLpro-300

Amgen

Phase 1 Completed

41 enrolled 19 charts

EndocrineGenitourinary

Neuroendocrine Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡